American Well (NYSE:AMWL) Insider Sells 5,575 Shares

American Well Corporation (NYSE:AMWL) insider Dmitry Zamansky sold 5,575 shares of the company’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $5.30, for a total value of $29,547.50. Following the sale, the insider directly owned 241,080 shares in the company, valued at $1,277,724. This represents a 2.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Dmitry Zamansky also recently made the following trade(s):

• On Friday, January 2nd, Dmitry Zamansky sold 6,243 shares of American Well stock. The shares were sold at an average price of $4.85, for a total value of $30,278.55.

American Well Stock Performance

Shares of AMWL traded up $0.22 during midday trading on Thursday, hitting $5.51. The company had a trading volume of 22,215 shares, compared to its average volume of 92,324. American Well Corporation has a 1 year low of $3.71 and a 1 year high of $9.15. The firm has a market capitalization of $91.12 million, a P/E ratio of -0.93 and a beta of 1.34. The company’s 50-day simple moving average is $5.20 and its 200-day simple moving average is $5.09.

American Well (NYSE:AMWL) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($1.52) EPS for the quarter, topping the consensus estimate of ($1.59) by $0.07. American Well had a negative net margin of 38.38% and a negative return on equity of 35.33%. The company had revenue of $55.31 million during the quarter, compared to analysts’ expectations of $52.71 million. Equities analysts predict that American Well Corporation will post -9.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on AMWL shares. Morgan Stanley decreased their price target on American Well from $10.50 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. Stifel Nicolaus decreased their target price on American Well from $6.00 to $5.00 and set a “hold” rating for the company in a research note on Friday, February 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of American Well in a report on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of American Well from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. One analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $7.42.

Institutional Trading of American Well

Several institutional investors and hedge funds have recently made changes to their positions in AMWL. Headlands Technologies LLC purchased a new position in American Well during the 2nd quarter worth approximately $39,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in American Well in the third quarter valued at approximately $62,000. Occudo Quantitative Strategies LP purchased a new stake in American Well in the fourth quarter valued at approximately $74,000. NewEdge Advisors LLC acquired a new stake in shares of American Well in the fourth quarter valued at approximately $82,000. Finally, Prelude Capital Management LLC acquired a new stake in shares of American Well in the third quarter valued at approximately $86,000. 56.05% of the stock is owned by hedge funds and other institutional investors.

American Well Company Profile

American Well, operating under the trade name Amwell, is a Boston-based digital health company that develops and delivers telehealth solutions to healthcare providers, payers, employers and patients. Through its cloud-based platform, the company enables secure virtual visits, remote patient monitoring and integrated care coordination across a range of medical disciplines, including primary care, behavioral health, chronic disease management and urgent care.

The company’s core offering, the Amwell Telehealth Platform, facilitates live video consultations, asynchronous messaging, e-prescribing and electronic health record integration.